Oncology News

Enhertu reduced the risk of disease progression or death by 50% vs. chemotherapy in patients with HER2-low mBC (HR-positive and HR-negative).

Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

Lynparza approved in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

Pivotal Phase 3 Data for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the NEJM,

Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for 1L Treatment of ER+, HER2- Metastatic Breast Cancer

Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer.

Merck’s KEYTRUDA® Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA NSCLC Regardless of PD-L1 Expression.

Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo Plus Yervoy in 1L Treatment of Patients with Metastatic NSCLC.

BMS to Acquire Turning Point Therapeutics. Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor for Patients with ROS1-positive 1L NSCLC.

Lilly Presents Updated Data on Retevmo® in Advanced RET Fusion-Positive NSCLC at the 2022 European Lung Cancer Congress. Among 69 treatment-naïve patients, the confirmed ORR was 84.1%.

Calquence plus obinutuzumab demonstrated sustained survival benefit in 1st-line chronic lymphocytic leukaemia with 90% of patients surviving five years in ELEVATE-TN trial.

Results from primary analysis of Phase 2 PILOT study shows Breyanzi delivered CR in more than half of patients with r/r large B-cell lymphoma after 1L therapy (transplant ineligible)

Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab for r/r MM. ORR was 60.6%.

Scemblix® shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of CML trial. 2X improvement in MMR rate vs. Bosulif® at 96 weeks (37.6% vs. 15.8%).

Data show a combination of teclistamab (BCMAxCD3 bispecific antibody) plus DARZALEX FASPRO® improved clinical efficacy in heavily pretreated patients with r/r MM. ORR of 76.5%.